Dec 7, 2020 4:05 pm EST Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
Nov 12, 2020 4:05 pm EST Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update
Oct 29, 2020 5:30 am EDT Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
Oct 27, 2020 5:30 am EDT Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020
Oct 8, 2020 6:30 am EDT Achieve Life Sciences Announces to Present at the MicroCap Best Ideas Conference, October 13, 2020
Oct 7, 2020 6:30 am EDT Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Sep 30, 2020 8:00 am EDT Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President
Sep 18, 2020 9:30 am EDT Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study